Table 1.
Demographic and clinical data of 33 participants with schizophrenia and 29 healthy controls
| Subject characteristics | Participants with schizophrenia | Healthy controls | Statistics | P value |
|---|---|---|---|---|
| Male/female | 19 / 14 | 17 / 12 | χ2 = 0.01 | 0.93a |
| Age (years) | 23.45 (4.05)b | 23.17 (3.05) | t = 0.31 | 0.11c |
| Education (years) | 13.67 (2.12) | 14.38 (1.97) | z = − 1.38 | 0.17d |
| Intracranial volume (ml) | 1647.35 (238.45) | 1645.73 (182.27) | z = − 0.15 | 0.88d |
| Age at onset (years) | 19.48 (3.37) | – | ||
| Duration of illness (months) | 41.27 (33.09) | – | ||
| Antipsychotic dose (mg/day)e | 437.27 (268.92) | – | ||
| PANSS positive score | 19.64 (4.49) | – | ||
| PANSS negative score | 15.94 (4.50) | – | ||
| PANSS total score | 67.79 (11.47) | – | ||
aPearson Chi-square test
bMean (standard deviation)
cTwo sample t-test
dMann-Whitney Test
eChloropromazine-equivalent dose
PANSS Positive and Negative Syndrome Scale